Key laboratory of Drug Targeting and Drug Delivery System, Ministry of Education, West China School of Pharmacy (W.-X.W., X.-W.T., Q.-H.L., Y.-J.C., J.Z., P.-P.Z., K.L.), Evidence-Based Pharmacy Center, Department of Pharmacy, West China Second University Hospital (L.C.), Labor And Delivery Room, West China Second University Hospital, (G.-Y.W., J.-L.Z.), Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, (L.C., G.-Y.W., J.-L.Z.), and Institute of Clinical Pharmacology, West China Hospital, (J.M.), Sichuan University, Chengdu, China; Metabolomics Shared Resource, University of Hawaii Cancer Center, Honolulu, Hawaii (M.-M.S., W.J.); State Key Laboratory of Drug Delivery Technology and Pharmacokinetics, Tianjin Institute of Pharmaceutical Research, Tianjin, China (C.-X.L.); and Chengdu Health-Balance Medical Technology Co., Ltd., Chengdu, China (W.-X.W., X.W.T., Q.-H.L., Y.-J.C., J.Z., P.-P.Z., K.L.).
Key laboratory of Drug Targeting and Drug Delivery System, Ministry of Education, West China School of Pharmacy (W.-X.W., X.-W.T., Q.-H.L., Y.-J.C., J.Z., P.-P.Z., K.L.), Evidence-Based Pharmacy Center, Department of Pharmacy, West China Second University Hospital (L.C.), Labor And Delivery Room, West China Second University Hospital, (G.-Y.W., J.-L.Z.), Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, (L.C., G.-Y.W., J.-L.Z.), and Institute of Clinical Pharmacology, West China Hospital, (J.M.), Sichuan University, Chengdu, China; Metabolomics Shared Resource, University of Hawaii Cancer Center, Honolulu, Hawaii (M.-M.S., W.J.); State Key Laboratory of Drug Delivery Technology and Pharmacokinetics, Tianjin Institute of Pharmaceutical Research, Tianjin, China (C.-X.L.); and Chengdu Health-Balance Medical Technology Co., Ltd., Chengdu, China (W.-X.W., X.W.T., Q.-H.L., Y.-J.C., J.Z., P.-P.Z., K.L.)
Drug Metab Dispos. 2020 Aug;48(8):662-672. doi: 10.1124/dmd.120.000011. Epub 2020 Jun 4.
This work aims to investigate how the bile acid metabolism of newborns differs from that of adults along the axis of primary, secondary, and tertiary bile acids (BAs). The total unconjugated BA profiles were quantitatively determined by enzyme digestion techniques in urine of 21 newborns born by cesarean section, 29 healthy parturient women, 30 healthy males, and 28 healthy nonpregnant females. As expected, because of a lack of developed gut microbiota, newborns exhibited poor metabolism of secondary BAs. Accordingly, the tertiary BAs contributed limitedly to the urinary excretion of BAs in newborns despite their tertiary-to-secondary ratios significantly increasing. As a result, the primary BAs of newborns underwent extensive oxidative metabolism, resulting in elevated urinary levels of some fetal-specific BAs, including 3-dehydroCA, 3,7,12-trihydroxy-5-cholan-24-oic acid, 3,12-oxo-hydroxy-5-cholan-24-oic acid, and nine tetrahydroxy-cholan-24-oic acids (Tetra-BAs). Parturient women had significantly elevated urinary levels of tertiary BAs and fetal-specific BAs compared with female control, indicating that they may be excreted into amniotic fluid for maternal disposition. An metabolism assay in infant liver microsomes showed that four Tetra-BAs and 3-dehydroCA were hydroxylated metabolites of cholate, glycocholate, and particularly taurocholate. However, the recombinant cytochrome P450 enzyme assay found that the fetal-specific CYP3A7 did not contribute to these oxidation metabolisms as much as expected compared with CYP3A4. In conclusion, newborns show a BA metabolism pattern predominated by primary BA oxidations due to immaturity of secondary BA metabolism. Translational studies following this finding may bring new ideas and strategies for both pediatric pharmacology and diagnosis and treatment of perinatal cholestasis-associated diseases. SIGNIFICANCE STATEMENT: The prenatal BA disposition is different from adults because of a lack of gut microbiota. However, how the BA metabolism of newborns differs from that of adults along the axis of primary, secondary, and tertiary BAs remains poorly defined. This work demonstrated that the urinary BA profiles of newborns born by cesarean section are characterized by oxidative metabolism of primary BAs, in which the fetal-specific CYP3A7 plays a limited role in the downstream oxidation metabolism of cholate.
本研究旨在探讨新生儿胆汁酸代谢在初级、次级和三级胆汁酸(BAs)轴上与成人的差异。通过酶消化技术定量测定了 21 名剖宫产新生儿、29 名健康产妇、30 名健康男性和 28 名健康未怀孕女性尿液中的总未结合 BA 谱。正如预期的那样,由于缺乏发育良好的肠道微生物群,新生儿次级 BAs 的代谢较差。因此,尽管三级 BA 与二级 BA 的比值显著增加,但三级 BA 对新生儿尿中 BA 的排泄贡献有限。结果,新生儿的初级 BA 经历了广泛的氧化代谢,导致一些胎儿特异性 BA 的尿中水平升高,包括 3-脱氢 CA、3,7,12-三羟基-5-胆烷-24-酸、3,12-氧代-羟基-5-胆烷-24-酸和九种四羟基-胆烷-24-酸(Tetra-BAs)。与女性对照组相比,产妇的尿中三级 BA 和胎儿特异性 BA 的水平显著升高,表明它们可能被排泄到羊水以供母体处置。婴儿肝微粒体代谢测定显示,四种 Tetra-BAs 和 3-脱氢 CA 是胆酸、甘胆酸和特别是牛磺胆酸的羟基化代谢物。然而,重组细胞色素 P450 酶测定发现,与 CYP3A4 相比,胎儿特异性 CYP3A7 对这些氧化代谢的贡献并不像预期的那样多。总之,由于次级 BA 代谢不成熟,新生儿的 BA 代谢模式以初级 BA 氧化为主。这项研究的结果可能为儿科药理学以及围产期胆汁淤积相关疾病的诊断和治疗带来新的思路和策略。
由于缺乏肠道微生物群,产前 BA 分布与成人不同。然而,新生儿的 BA 代谢如何在初级、次级和三级 BA 轴上与成人不同仍不清楚。本研究表明,剖宫产新生儿的尿 BA 谱特征为初级 BA 的氧化代谢,其中胎儿特异性 CYP3A7 在胆酸的下游氧化代谢中发挥有限作用。